Hizip 90 Tablet contains Etoricoxib 90 mg, a selective cyclooxygenase-2 (COX-2) inhibitor used primarily for the management of pain and inflammation associated with various musculoskeletal and inflammatory conditions. Etoricoxib exerts its therapeutic effect by selectively inhibiting the COX-2 enzyme, which plays a key role in the synthesis of prostaglandins responsible for pain and inflammation, while sparing COX-1, thus reducing the risk of gastrointestinal adverse effects commonly seen with non-selective NSAIDs. Hizip 90 is indicated for the relief of symptoms in osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and acute gouty arthritis. It is also effective in managing acute musculoskeletal pain and postoperative dental pain. The recommended dosage and duration of treatment should be individualized based on the patient's clinical condition and response to therapy, with caution advised in patients with cardiovascular risk factors, renal or hepatic impairment. Common side effects may include headache, dizziness, hypertension, and gastrointestinal discomfort. Hizip 90 should be used under medical supervision, particularly in patients with a history of cardiovascular disease, gastrointestinal ulcers, or bleeding disorders. Regular monitoring is recommended to ensure efficacy and safety during treatment.